政策、减值等因素影响单季度利润，服务、产品业务有望持续向好 迪安诊断（300244）/医疗器械 证券研究报告/公司点评 2024 年 5 月 14 日 请务必阅读正文之后的重要声明部分 公司点评 来源：wind，中泰证券研究所 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |----------------|----------------------------------------------|----------|---------|---------|---------|----------|----------|----------|----------|----------|----------| | 图表 4 | ：迪安诊断分季度财务数据（百万元） \n2021-3Q | 2021-4Q | 2022-1Q | 2022-2Q | 2022-3Q | 2022-4Q | 2023-1Q | 2023-2Q | 2023-3Q | 2023-4Q | 2024-1Q | | 营业收入 | 3,5 ...

Investment Rating - The report maintains a "Buy" rating for the company, citing its "product + service" dual-drive strategy and significant resource advantages [9] Core Views - The company's ICL business achieved a 17% year-over-year growth in 2023, with the proportion of revenue from tertiary hospitals reaching a new high [3] - The company's diagnostic service business achieved a revenue of 5.187 billion yuan in 2023, an 11.91% year-over-year increase, with ICL revenue reaching 4.718 billion yuan, a 16.73% increase [19] - The company's IVD product business achieved a revenue of 8.686 billion yuan in 2023, with channel product revenue growing by 5.32% to 8.283 billion yuan, and self-developed product revenue reaching 403 million yuan [20] - The company's profitability declined in 2023, with a 5.87 percentage point decrease in gross margin to 31.29%, and a 4.85 percentage point decrease in net profit margin to 4.34% [20] - The company's accounts receivable decreased by 1.902 billion yuan in 2023, and operating cash flow increased by 17.20% to 1.921 billion yuan [5][7] - The company's revenue in Q1 2024 was 2.973 billion yuan, a year-over-year decrease of 8.01%, with ICL revenue growing by 10.41% to 1.071 billion yuan [7] Business Performance - The company's new testing projects in 2023 reached 1,023, with special inspection revenue reaching 2.049 billion yuan, accounting for 39.50% of traditional diagnostic revenue [2] - The company's infectious disease projects grew by 142% year-over-year, neuroimmunology projects grew by 102%, and hematology projects grew by 69% [2] - The company added 238 new tertiary hospital customers in 2023, with tertiary hospital revenue accounting for 32.8% of total revenue [2] - The company added 46 new共建 laboratories in 2023, bringing the total to nearly 700, with business revenue growing by 26% [4] - The company added 27 new precision centers in 2023, bringing the total to 70, with 31 achieving profitability and business revenue growing by 34% [4] Financial Projections - The company's revenue is expected to grow to 14.543 billion yuan in 2024, 16.092 billion yuan in 2025, and 17.832 billion yuan in 2026, with year-over-year growth rates of 8.47%, 10.65%, and 10.82% respectively [10] - The company's net profit attributable to the parent company is expected to grow to 610 million yuan in 2024, 843 million yuan in 2025, and 1.015 billion yuan in 2026, with year-over-year growth rates of 98.29%, 38.29%, and 20.36% respectively [10] - The company's diluted EPS is expected to be 0.97 yuan in 2024, 1.34 yuan in 2025, and 1.62 yuan in 2026 [10] - The company's PE ratio is expected to be 15.57 in 2024, 11.26 in 2025, and 9.35 in 2026 [10] Industry Outlook - The diagnostic industry still has significant growth potential, and the company's dual-drive strategy of "product + service" is expected to continue to generate significant resource advantages [9]

% 1 个月 3 个月 12 个月 核心要点： Email：jiangdong@xcsc.com 费用率方面，管理费用率 7.06%，同比提升 0.81pct；财务费用率为 1.65%， 同比上升 0.17pct，销售费用率 10.32%，同比上升 2.44pct，全年公司研发 投入 4.36 亿元，同比下降 31.98%。公司整体期间费用绝对值大幅下降，但 费用率有所提升，主要是由于新冠抗原需求下降，市场推广费减少，但相 应营收也大幅下降使得费用率有所提升，同时公司持续加大创新研发投入， 带动研发费用有所提升。公司 2023 年毛利率为 31.29%，同比下降 5.87pct， 预计毛利率大幅下降主要是由于新冠检测收入下降所致；2023 年公司净利 率 4.34%，同比下降 4.85pct。 公司受应急诊断服务业务下降影响业绩承压，但其内生增长稳健且应收账 款风险逐渐释放。预计 2024-2026 年公司营收分别为 145.54/158.05/170.66 亿元，归母净利润分别为6.10/7.98/9.91亿元，对应EPS分别为0.97/1.27/1.58 元，首次覆盖我们给予"增持"评级。 公司研究 | ...

各位投资者 大家下午好 我是中金的张庆欢迎参加DN审战二十三年的年报及二十四年一季报的业绩电话会在线的还有我们团队的余波和陈诗雨本次电话会是由中金 中泰 银河 华创 天峰 剑投 信达 新业 华安 太平洋 中游几家券商共同主持 公司在年前这个节前也披露了年报和季报考虑到希望能让更多的这个管理领导出席参加交流那业绩的解读电话会我们放到了节后召开感谢大家的一个时间那出席本次的这个公司的这个管理团队的领导也非常的豪华就是参与出席领导包括董事长 嘉宾总然后执行总裁 助演总 高级副总裁 洪汉华总财务负责人赵德康总首席信息官吴维延总以及总秘陶军总感谢各位领导的一个时间从公司已经披露的这个财务报表大家其实也会看到公司在2023年的费用端减值端有一个明显的压力释放2024年对于公司来说也是一个轻装上阵的一年但与此同时公司在资产产品国际化层面也有比较多的这样的一个突破这个包括节前越南迪安克 谢谢张静各位证券投资的朋友大家好感谢大家来参与迪安的业绩交流会我首先还是想把迪安这个季度的业绩跟大家做一个汇报 那么应该讲2020年的一季度的话我们实现的营业收入是29.73亿较去年同期时下降了8.01%实现规模经历的是0.23亿元较去年同期 ...

本次回购符合公司回购股份方案及相关法律法规的要求。 证券代码：300244 证券简称：迪安诊断 公告编号：2024-038 迪安诊断技术集团股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 迪安诊断技术集团股份有限公司（以下简称"公司"）于2024年2月6日召开 第五届董事会第四次会议审议通过了《关于回购公司股份方案的议案》，同意 使用自有资金以集中竞价交易方式回购公司人民币普通股A股股份（以下简称 "本次回购"），用于实施员工持股计划或者股权激励。回购金额不低于人民币 10,000万元（含）且不超过人民币20,000万元（含），回购价格不超过人民币28 元/股（含），回购期限自董事会审议通过本次回购股份方案之日起12个月内。 具体内容详见公司于2024年2月7日在巨潮资讯网披露的《关于回购公司股份方 案的公告》《回购报告书》。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等相关规定，公司在回购期间应当在每个月的前三个交易 日内披露截至上月末的回购进展情况。现将公司截至上月末的回 ...

Key Points 1. Participants and Hosts - The earnings call is hosted by a group of securities firms, including Zhongjin, Zhongtai, Galaxy, Huachao, Tianfeng, Jiantou, Xinda, Xinye, Huawan, and Taipingyang. - Zhongjin's Zhang Qing and team members Yu Bo and Chen Shiyu are present. - [1] 2. Company and Report Overview - The call focuses on the annual report and first quarter report of DN Company. - [1]

[Table_Header] （一）公司财务预测表 分析师承诺及简介 | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------|----------|------------|-----------------------------------| | [Table_RatingStandard] 评级标准 评级 说明 | | | | | | | 推荐： | 相对基准指数涨幅 10% 以上 | | 评级标准为报告发布日后的 6 到 12 个月行业指 | 行业评级 | 中性： | 相对基准指数涨幅在 -5%～10% 之间 | | 数（或公司股价）相对市场表现，其中： A 股市 场以沪深 300 指数为基准，新三板市场以三板成 | | 回避： | 相对基准指数跌幅 5% 以上 | | 指（针对协议转让标的）或三板做市指数（针对 | | 推荐： | 相对基准指数涨幅 20% 以上 | | 做市转让标的）为基准，北交所市场以北证 50 ...

迪[Ta安ble诊_Sto断ckN（ameRptType] 300244） 公司研究/公司点评 特检持续发力，期待长期增长 | --- | --- | --- | --- | |-------|------------------------------------------------------------------------------------------------------------------|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

证券代码：300244 证券简称：迪安诊断 公告编号：2024-037 表决结果：同意 3 票，反对 0 票，弃权 0 票。 二、审议《关于会计政策变更的议案》 本次会计政策变更是公司根据国家财政部相关文件要求进行的合理变更，符 合《企业会计准则》等相关规定，能够更加客观、公允地反映公司的财务状况和 经营成果，不会对公司当期财务状况、经营成果和现金流量产生重大影响。本次 会计政策变更的决策程序符合相关法律、法规和《公司章程》的规定，不存在损 害公司及股东利益的情形。 迪安诊断技术集团股份有限公司 第五届监事会第四次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年 4 月 26 日上午 10 点，迪安诊断技术集团股份有限公司（以下简称 "公司"或"迪安诊断"）以通讯表决方式召开了第五届监事会第四次会议。召 开本次会议的通知已于 2024 年 4 月 23 日以短信、电子邮件等方式通知全体监事。 会议由公司监事会主席师玉鹏先生召集和主持。本次监事会应到监事 3 名，实到 监事 3 名，符合《公司法》和《公司章程》的规定。本次会议，经表决通 ...

Financial Performance - The company's revenue for Q1 2024 was ¥2,973,005,617.76, a decrease of 8.01% compared to the same period last year[5]. - Net profit attributable to shareholders was ¥23,170,466.54, down 85.54% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was ¥23,536,277.50, representing an 83.01% decline from the previous year[5]. - The net profit for the current period is 76,393,132.63, a decrease from 254,851,363.05 in the previous period, representing a decline of approximately 70%[29]. - The total profit for the current period is 101,365,629.84, down from 355,241,974.73, indicating a decrease of about 71%[29]. - The operating profit for the current period is 102,858,253.38, compared to 360,492,005.57 in the previous period, reflecting a decline of approximately 71%[29]. - Basic earnings per share for the current period is 0.0371, down from 0.2557 in the previous period, indicating a decrease of approximately 85%[30]. - The total comprehensive income attributable to the parent company is 23,169,898.96, a significant drop from 160,273,989.61 in the previous period, representing a decline of about 86%[30]. - The total comprehensive income attributable to minority shareholders is 53,222,666.09, compared to 94,577,373.44 in the previous period, indicating a decrease of approximately 44%[30]. Cash Flow and Liquidity - The cash flow from operating activities was -¥266,945,833.56, a 16.71% increase in negative cash flow compared to last year[5]. - The cash flow from operating activities shows a net outflow of 266,945,833.56, compared to a net outflow of 228,725,675.95 in the previous period[30]. - The cash flow from investing activities resulted in a net outflow of 459,639,091.92, compared to a net outflow of 75,059,602.72 in the previous period[31]. - The cash flow from financing activities generated a net inflow of 35,668,498.90, contrasting with a net outflow of 301,079,035.95 in the previous period[31]. - Cash and cash equivalents decreased to CNY 2.27 billion from CNY 2.97 billion, reflecting a reduction in liquidity[24]. - Cash and cash equivalents at the end of the period amount to 2,256,555,242.50, down from 3,540,080,774.49 at the end of the previous period[31]. - Cash and cash equivalents at the end of Q1 2024 were not specified but are critical for assessing liquidity[48]. Assets and Liabilities - Total assets at the end of the reporting period were ¥17,855,213,090.08, a decrease of 0.47% from the end of the previous year[5]. - The company's total assets amounted to CNY 17,855,213,090.08, a slight decrease from CNY 17,939,311,256.63 at the end of the previous quarter[44]. - Total liabilities decreased to CNY 7,945,903,437.23 from CNY 8,034,531,783.60, indicating a reduction of 1.11%[44]. - Long-term receivables decreased by 38.98% to CNY 15.65 million due to the recovery of matured receivables[17]. - Long-term equity investments increased by 46.26% to CNY 980.51 million, primarily due to the acquisition of equity in an associate[17]. - The equity attributable to shareholders of the parent company was CNY 7,497,593,403.99, down from CNY 7,566,265,438.86[45]. Operational Highlights - The diagnostic services business generated revenue of ¥1,149,000,000, a decrease of 5.97% year-over-year, while ICL revenue was ¥1,071,000,000, showing a growth of 10.41%[8]. - The company is focusing on cost reduction and efficiency improvement through supply chain optimization and strategic business deepening[8]. - The company is increasing R&D investment in key disease areas and business model solutions, particularly in LDT, IVD, and digital intelligence[8]. - The company is accelerating its international business expansion to tap into overseas markets for its products and services[8]. - Research and development expenses decreased to CNY 72,330,627.47 in Q1 2024 from CNY 99,924,701.55 in Q1 2023, reflecting a reduction of 27.77%[45]. Shareholder Actions - The company repurchased 5,032,500 shares, accounting for 0.80% of the total share capital, with a total transaction amount of CNY 91.32 million[23]. - The company plans to use between CNY 100 million and CNY 200 million for share repurchase to implement employee stock ownership plans or equity incentives[23].